Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
1991-8-14
pubmed:abstractText
All patients with chronic myelogenous leukemia (CML) undergo clinical transition from chronic to acute phase. This transition is often associated with deletion of the short arm of chromosome 17 in the form of the i(17q) aberration. Since the p53 gene is a suppressor gene and is located on 17p13, we examined the possibility that it is inactivated during progression of CML. Therefore, we studied the structure and expression of p53 in the leukemic cells of a large number of CML patients in acute phase. We found that although the gene is rarely rearranged, one p53 allele is completely deleted in patients with the i(17q) aberration as well as in some patients who do not show karyotypic changes. In all of these patients the remaining allele is inactivated through loss of expression, rearrangement, or point mutation. Detailed analysis of some patients who carry both p53 alleles indicated neither loss of expression nor structural alterations. It appears that p53 loss of function is associated with progression of around 25% of CML patients.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-14427847, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-1967214, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2142762, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2143022, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2359461, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2406902, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2440339, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2487158, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2525423, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2530586, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2531845, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2554494, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2572286, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2581632, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2687768, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2725497, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2771957, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2823272, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2825022, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2946935, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2982232, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-2989692, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-3101769, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-3199845, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-3280726, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-3312834, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-3456488, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-3858609, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-3990796, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-4126434, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-6091099, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-6204766, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-6319012, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-6751036, http://linkedlifedata.com/resource/pubmed/commentcorrection/2068108-6772444
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
88
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6293-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:2068108-Base Composition, pubmed-meshheading:2068108-Base Sequence, pubmed-meshheading:2068108-Cell Line, pubmed-meshheading:2068108-Chromosomes, Human, Pair 22, pubmed-meshheading:2068108-Chromosomes, Human, Pair 9, pubmed-meshheading:2068108-Gene Rearrangement, pubmed-meshheading:2068108-Genes, Tumor Suppressor, pubmed-meshheading:2068108-Humans, pubmed-meshheading:2068108-Leukemia, Myelogenous, Chronic, BCR-ABL Positive, pubmed-meshheading:2068108-Leukemia, Myeloid, Acute, pubmed-meshheading:2068108-Models, Structural, pubmed-meshheading:2068108-Molecular Sequence Data, pubmed-meshheading:2068108-Mutation, pubmed-meshheading:2068108-Nucleic Acid Conformation, pubmed-meshheading:2068108-RNA, Neoplasm, pubmed-meshheading:2068108-Restriction Mapping, pubmed-meshheading:2068108-Translocation, Genetic, pubmed-meshheading:2068108-Tumor Suppressor Protein p53
pubmed:year
1991
pubmed:articleTitle
p53 in chronic myelogenous leukemia in acute phase.
pubmed:affiliation
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't